|
|
Volumn 16, Issue 6, 2015, Pages 596-597
|
|
The role of regorafenib in metastatic colorectal cancer
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
BEVACIZUMAB;
BILIRUBIN;
EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY;
NUCLEOSIDE ANALOG;
PLACEBO;
REGORAFENIB;
TAS 102;
UNCLASSIFIED DRUG;
ANTINEOPLASTIC AGENT;
CARBANILAMIDE DERIVATIVE;
PYRIDINE DERIVATIVE;
ANEMIA;
ANTINEOPLASTIC ACTIVITY;
ASIAN;
BILIRUBIN BLOOD LEVEL;
CANCER CHEMOTHERAPY;
CANCER SURVIVAL;
DRUG APPROVAL;
DRUG EFFICACY;
DRUG TOLERABILITY;
ENZYME INHIBITION;
HAND FOOT SYNDROME;
HUMAN;
LIVER FUNCTION TEST;
MEDICAL LITERATURE;
METASTATIC COLORECTAL CANCER;
MULTICENTER STUDY (TOPIC);
NEUTROPENIA;
NOTE;
OUTCOME ASSESSMENT;
OVERALL SURVIVAL;
PATIENT SELECTION;
PHASE 3 CLINICAL TRIAL (TOPIC);
PRIORITY JOURNAL;
PROGRESSION FREE SURVIVAL;
RANDOMIZED CONTROLLED TRIAL (TOPIC);
RISK BENEFIT ANALYSIS;
SIDE EFFECT;
SURVIVAL RATE;
SURVIVAL TIME;
TREATMENT DURATION;
COLORECTAL NEOPLASMS;
FEMALE;
MALE;
ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;
COLORECTAL NEOPLASMS;
FEMALE;
HUMANS;
MALE;
PHENYLUREA COMPOUNDS;
PYRIDINES;
|
|
EID: 84930247743
PISSN: 14702045
EISSN: 14745488
Source Type: Journal
DOI: 10.1016/S1470-2045(15)70191-9 Document Type: Note |
|
Times cited : (11)
|
|
References (5)
|
